High percentage of responders to acei as a significant success factor in the treatment of hypertension

High blood pressure (BP) is the leading cause of premature death, with about 10 million deaths and over 200 million inabilities according to age. Despite treatment, this disability has increased in 40% of the population with hypertension (HTN). New recommendations for the treatment of HTN emphasize the importance of improving BP control where, for majority of patients, the best approach is to use 1 or 2 drugs with a simple algorithm. The inhibitors of angiotensin converting enzyme or angiotensin receptor blockers (ACEI or ARB) are the first line drugs alone or in combination with calcium channel blockers (CCS) and/or diuretics. We analyzed the treatment of HTN, with a focus on the use of cilazapril as an effective, long-acting ACEI. Cilazapril has shown efficacy in a single dose and good tolerability as monotherapy but also in combination with hydrochlorothiazide in all hypertensive groups as well as in special subgroups of patients such as the elderly, patients with impaired renal function, heart failure patients, chronic obstructive pulmonary disease. Dose titration and addition of diuretics lead to optimization of BP control and a high level of responders, which directly reduces the risk of adverse cardiovascular (CV) events.